Deutsche Version

The TRU-ID is situated at the heart of the University Hospital Cologne campus. In our modern laboratories covering biosafety levels (BSL) one to three at the Center for Molecular Medicine Cologne (CMMC) and the Translational Research in Infectious Diseases and Oncology (TRIO) research building, we do exciting research on viral, bacterial and fungal pathogens. Our activities are directed at translational research with the ultimate goal of improving patient wellbeing. The central localization of our unit allows for timely processing of patient material in several bedside-to-bench studies.

A key unit is the modern BSL3 facility, which is maintained under negative air pressure for pathogen containment. The facility is dedicated to the identification of novel bioactive substances against SARS-CoV2, multidrug-resistant tuberculosis and other highly contagious pathogens. Our research also seeks to answer fundamental scientific questions about host-pathogen interactions, again with the goal of future clinical application as host-directed therapies, new vaccines and diagnostics. To this end, six research groups with different scientific backgrounds have joined forces to form TRU-ID in order to create synergies. In addition, there are various collaborations with laboratories within and outside the University Hospital of Cologne.

Tony Müller, PhD
Lab manager TRU-ID

Center for Molecular Medicine Cologne (CMMC)/ TRIO research building
Robert Koch Str. 21
50931 Cologne

Phone +49 221 478-39428
Email tony.mueller@uk-koeln.de